17,261 trials
Streptococcal Infections · Gram-Positive Bacterial Infections · Bacterial Infections
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in Maternal Subjects and Infants at Delivery/Birth — 2.07; 2.31; 3.98; 1.01 μg/mL
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Myeloma · Lymphoma
Primary: Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis — 9; 17 participants
Obesity
Primary: Percent Change From Baseline in Body Mass Index at 3-months — -2.9; -0.15 percentage of change in BMI
Hemostasis
Primary: Proportion of Subjects Achieving Hemostatic Success — 98.3; 53.3; 98.0 percentage of success
Prostate Cancer
Primary: Number of Participants With > = Grade 2 Autoimmune Events or >=Toxicities at Least Possibly Related to pTVG-HP With GM-CSF Study Treatment. — 1; 0 participants
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Dose-limiting Toxicity (DLT) (Phase I) — 1; 1 participants
Lymphoma
Primary: Overall Survival Median — 1299 days
Narcolepsy
Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last…
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With a Best Clinical Response of Clinical Remission (CR) — 73.7; 94.7; 63.2; 78.9 percentage of participants
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Everolimus With Panobinostat — 10; 20 mg, orally
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD) — 25; 1.3; 20; 30 mg
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Hepatitis C
Primary: Segment 1: Safety — 93.3; 100.0; 93.8; 100.0 percentage of participants
Acute Myocardial Infarction
Primary: Change in Left Ventricular End-Systolic Volume Index — -2.1; -4.6 mL of blood/meter^2 body surface area — p=0.97